On May 14, Ge Longhui | Boji Pharmaceutical (300404.SZ) said on the investor interactive platform that currently the company provides customers with clinical research services for “simeglutide injections” to treat diabetes and obesity, as well as clinical research services for the treatment of diabetics with cell therapy. Currently, related projects are still being developed and are progressing smoothly.
博济医药(300404.SZ)：目前有为客户提供“司美格鲁肽注射液”治疗糖尿病及肥胖的临床研究服务
Boji Pharmaceutical (300404.SZ): Currently provides customers with clinical research services for the treatment of diabetes and obesity with “simeglutide injection”
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.